CTI announces partnership for oncology drug development
The collaboration brings together CTI’s clinical and regulatory expertise with Crown Bioscience’s preclinical and translational models, aiming to streamline the transition of oncology compounds from discovery to early-phase global studies. It is set to benefit customers by providing expert guidance that enhances the efficiency of oncology drug development.
CTI Global Laboratory Services business development vice-president Ryan Gifford stated: “Crown Bioscience’s leadership in early-phase oncology research and suite of preclinical services complement CTI’s broad spectrum of capabilities. Together, we can offer enhanced support to our oncology clients and deepen our commitment to advancing cancer research.”
The combined expertise is expected to ensure an effective path to clinic, support long-term success in drug development and accelerate the delivery of new oncology treatments to patients.
Through the alliance, customers will have access to a range of consulting services designed to foster an integrated approach to drug development. These services include strategic preclinical development planning, study data analysis and interpretation, de novo assay development and regulatory guidance.
Crown Bioscience commercial senior vice-president Alex Slater stated: “Crown Bioscience has an established reputation for exceeding the typical services offered by a regular CRO (contract research organisation).This initiative unites deep-seated expertise spanning all phases of drug development, marking a pivotal step towards delivering a true translational offer to our clients.”
In November 2023, Crown Bioscience launched its service offering, OrganoidXplore to meet the demands of research initiatives by offering a diverse selection of models that cover a wide spectrum of genetic backgrounds and mutations.
